Huvepharma announced today its acquisition of AgriLabs in a move it says will expand the U.S. presence of the global animal health and nutrition company and speed commercialization of its biologic solutions for animal health.
“We’re very excited about the talent and technology that are part of the AgriLabs businesses,” said Glen Wilkinson, president of Huvepharma USA. “This acquisition furthers Huvepharma’s strategy in creating a balanced portfolio of products and enhancing our presence in the global market. It also enables more rapid commercialization of biological products through Benchmark Biolabs, a subsidiary of AgriLabs and part of the acquisition of companies.”
The acquisition includes the AgriLabs product lines Colostrx CS and Colostrx CR; I-Site XP, MpB Guard and Pulmo-Guard PH-M vaccines; the VetGun insecticide delivery system, and AgriLabs’ custom vaccines business. In addition, the acquisition also includes Antelope Valley Bios, a contract manufacturing business, and the VaxLiant portfolio of novel adjuvants based in Lincoln, Neb.
“We’re pleased to be a part of Huvepharma’s global animal health company as this acquisition will provide resources to bring new solutions to veterinarians and producers more quickly,” said Steve Schram, president and chief executive officer of AgriLabs. “It will also allow us to accelerate the development of the ExactVac DNA vaccine with ENABL adjuvant, which represents the next generation of biological innovation in animal health.”
Both companies will continue operations under their current identities as integration opportunities are identified in 2018.
“Huvepharma and AgriLabs are strong, complementary businesses focused on providing real solutions for the animal food producing industry,” Wilkinson said. “This acquisition only strengthens our ability to provide the highest-quality products and services as Huvepharma’s commitment to serving our customers.”